United Therapeutics Corp revenue
United Therapeutics Corp's revenue was $3.18bn in fiscal 2025, up 10.6% on the year before. Since fiscal 2009 ($359m) it has grown at a compound 14.6% a year. Over the last twelve months it was $3.15bn.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 359 | 593 | 743 | 916 | 1,117 | 1,289 | 1,466 | 1,599 | 1,725 | 1,628 | 1,449 | 1,483 | 1,686 | 1,936 | 2,328 | 2,877 | 3,183 | 3,155 |
| Growth on the year before | — | +65.2% | +25.3% | +23.3% | +21.9% | +15.4% | +13.8% | +9.1% | +7.9% | −5.7% | −11.0% | +2.4% | +13.6% | +14.9% | +20.2% | +23.6% | +10.6% | — |
| Gross profit | 317 | 524 | 652 | 787 | 976 | 1,154 | — | 1,526 | 1,620 | 1,429 | 1,331 | 1,375 | 1,563 | 1,785 | 2,070 | 2,568 | 2,798 | 2,717 |
| Gross margin | 88.3% | 88.4% | 87.8% | 85.9% | 87.4% | 89.5% | — | 95.5% | 93.9% | 87.8% | 91.9% | 92.7% | 92.7% | 92.2% | 88.9% | 89.2% | 87.9% | 86.1% |
Where the revenue comes from
| Line of business | Revenue | YoY |
|---|---|---|
| Tyvaso | $1.9B | ▲ 15.9% |
| Tyvaso DPI | $1.3B | ▲ 25.0% |
| Nebulized Tyvaso | $586M | ▼ 0.2% |
| Remodulin | $527M | ▼ 2.1% |
| Orenitram | $497M | ▲ 14.4% |
| Unituxin | $227M | ▼ 5.0% |
| Adcirca | $30M | ▲ 26.1% |
| Other | $24M | ▲ 8.6% |
These categories overlap or exclude eliminations, so shares aren't shown.
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $3B | 95.4% | ▲ 10.9% |
| Outside the US | $146M | 4.6% | ▲ 5.8% |
From United Therapeutics Corp's 10-K filed February 25, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| United Therapeutics Corp | $3.15bn | 2.5% | 14.3% |
| Biontech SE | $3.24bn | 9.0% | — |
| Biomarin Pharmaceutical Inc | $3.41bn | 11.2% | 15.1% |
| Natera, Inc. | $2.71bn | 37.8% | 42.7% |
| Neurocrine Biosciences Inc | $3.70bn | 38.0% | 27.5% |
| Exelixis, Inc. | $2.50bn | 9.1% | 12.1% |
Compare with peers
- Biontech SE revenue
- Biomarin Pharmaceutical Inc revenue
- Natera, Inc. revenue
- Neurocrine Biosciences Inc revenue
- Exelixis, Inc. revenue
Head to head: BNTX vs UTHRBMRN vs UTHRNTRA vs UTHREXEL vs UTHR
More: Biotechnology stocks compared, Health Care sector, rankings of US companies